Literature DB >> 28806440

Considerations on the Off-label Use of Ketamine as a Treatment for Mood Disorders.

Samuel T Wilkinson1,2, Gerard Sanacora1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28806440      PMCID： PMC6248331          DOI： 10.1001/jama.2017.10697

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  5 in total

1.  A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression.

Authors:  Jaskaran B Singh; Maggie Fedgchin; Ella J Daly; Peter De Boer; Kimberly Cooper; Pilar Lim; Christine Pinter; James W Murrough; Gerard Sanacora; Richard C Shelton; Benji Kurian; Andrew Winokur; Maurizio Fava; Husseini Manji; Wayne C Drevets; Luc Van Nueten
Journal:  Am J Psychiatry       Date:  2016-04-08       Impact factor: 18.112

2.  Dose-Related Effects of Adjunctive Ketamine in Taiwanese Patients with Treatment-Resistant Depression.

Authors:  Tung-Ping Su; Mu-Hong Chen; Cheng-Ta Li; Wei-Chen Lin; Chen-Jee Hong; Ralitza Gueorguieva; Pei-Chi Tu; Ya-Mei Bai; Chih-Ming Cheng; John H Krystal
Journal:  Neuropsychopharmacology       Date:  2017-05-11       Impact factor: 7.853

Review 3.  Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression.

Authors:  D Jeffrey Newport; Linda L Carpenter; William M McDonald; James B Potash; Mauricio Tohen; Charles B Nemeroff
Journal:  Am J Psychiatry       Date:  2015-10       Impact factor: 18.112

Review 4.  A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders.

Authors:  Gerard Sanacora; Mark A Frye; William McDonald; Sanjay J Mathew; Mason S Turner; Alan F Schatzberg; Paul Summergrad; Charles B Nemeroff
Journal:  JAMA Psychiatry       Date:  2017-04-01       Impact factor: 21.596

5.  A Survey of the Clinical, Off-Label Use of Ketamine as a Treatment for Psychiatric Disorders.

Authors:  Samuel T Wilkinson; Mesut Toprak; Mason S Turner; Steven P Levine; Rachel B Katz; Gerard Sanacora
Journal:  Am J Psychiatry       Date:  2017-07-01       Impact factor: 18.112
  5 in total
  10 in total

1.  Acute and Longer-Term Outcomes Using Ketamine as a Clinical Treatment at the Yale Psychiatric Hospital.

Authors:  Samuel T Wilkinson; Rachel B Katz; Mesut Toprak; Ryan Webler; Robert B Ostroff; Gerard Sanacora
Journal:  J Clin Psychiatry       Date:  2018-07-24       Impact factor: 4.384

Review 2.  [Ketamine in the therapy of chronic pain and depression].

Authors:  Wolfgang Jaksch; Rudolf Likar; Martin Aigner
Journal:  Wien Med Wochenschr       Date:  2019-04-12

Review 3.  Use of ketamine and esketamine for depression: an overview of systematic reviews with meta-analyses.

Authors:  Tácio de Mendonça Lima; Marília Berlofa Visacri; Patricia Melo Aguiar
Journal:  Eur J Clin Pharmacol       Date:  2021-10-27       Impact factor: 2.953

Review 4.  Ketamine for treatment of mood disorders and suicidality: A narrative review of recent progress.

Authors:  Michael D Kritzer; Nicholas A Mischel; Jonathan R Young; Christopher S Lai; Prakash S Masand; Steven T Szabo; Sanjay J Mathew
Journal:  Ann Clin Psychiatry       Date:  2022-02       Impact factor: 2.691

Review 5.  Key considerations for the use of ketamine and esketamine for the treatment of depression: focusing on administration, safety, and tolerability.

Authors:  Michael D Kritzer; Chi-Un Pae; Prakash S Masand
Journal:  Expert Opin Drug Saf       Date:  2022-04-29       Impact factor: 4.011

Review 6.  Addictive potential of novel treatments for refractory depression and anxiety.

Authors:  Dusan Kolar
Journal:  Neuropsychiatr Dis Treat       Date:  2018-06-12       Impact factor: 2.570

7.  Acute cognitive effects of single-dose intravenous ketamine in major depressive and posttraumatic stress disorder.

Authors:  Margaret T Davis; Nicole DellaGiogia; Paul Maruff; Robert H Pietrzak; Irina Esterlis
Journal:  Transl Psychiatry       Date:  2021-04-08       Impact factor: 6.222

8.  Repeated or Continuous Medically Supervised Ketamine Administration Associated with Hepatobiliary Adverse Events: A Retrospective Case Series.

Authors:  Samantha Cotter; Jennie Wong; Neha Gada; Rajdeep Gill; S Christopher Jones; Grace Chai; Daniel Foster; Mark Avigan; Mallika Mundkur
Journal:  Drug Saf       Date:  2021-10-26       Impact factor: 5.606

Review 9.  Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor.

Authors:  Yan Wei; Lijia Chang; Kenji Hashimoto
Journal:  Mol Psychiatry       Date:  2021-05-07       Impact factor: 15.992

10.  Pharmacodynamic Interactions Between Ketamine and Psychiatric Medications Used in the Treatment of Depression: A Systematic Review.

Authors:  Jolien K E Veraart; Sanne Y Smith-Apeldoorn; Iris M Bakker; Berber A E Visser; Jeanine Kamphuis; Robert A Schoevers; Daan J Touw
Journal:  Int J Neuropsychopharmacol       Date:  2021-10-23       Impact factor: 5.176
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.